Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001171843-18-003822
Filing Date
2018-05-10
Accepted
2018-05-10 16:06:08
Documents
4
Period of Report
2018-06-20
Effectiveness Date
2018-05-10

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT def14a_051018.htm DEF 14A 485237
2 GRAPHIC logo.jpg GRAPHIC 4142
3 GRAPHIC proxycard_1.jpg GRAPHIC 56056
4 GRAPHIC proxycard_2.jpg GRAPHIC 35463
  Complete submission text file 0001171843-18-003822.txt   618502
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 18822485
SIC: 2836 Biological Products, (No Diagnostic Substances)